Glick, B., E. Lain, T. Lin, and R. Israel. “Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S30, doi:10.25251/skin.3.supp.30.